Clinical Trial Update: Tazemetostat and Palbociclib With CPX-351for R/R AML [Phase 1]

View source ↗

Summary

A Phase 1 trial from Thomas Jefferson University is evaluating a triple combination of tazemetostat, palbociclib, and CPX-351 for recurrent or refractory acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Palbociclib (palbociclib)
• Tazemetostat (tazemetostat)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING